Nicole Asamoah

Nicole Asamoah

Auto-generated profile, based on publicly available information

Nicole Asamoah

From the, Michael G. DeGroote School of Medicine, McMaster University, St. Catharines, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
NANicole Asamoah
Nicole Asamoah
MBMiranda K. Branyiczky
Miranda K. Branyiczky
AAAbdullah Almuqrin
Abdullah Almuqrin
FAFares Alkhayal
Fares Alkhayal
NSNoor Sakka
Noor Sakka
MAMohannad Abu-Hilal
Mohannad Abu-Hilal

28 July 2026 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JHJaehyun Hwang
Jaehyun Hwang
SGSana Gupta
Sana Gupta
EMEric McMullen
Eric McMullen
BABrendan Amoyaw
Brendan Amoyaw
SLSanaz Lordfard
Sanaz Lordfard
JDJeffrey Donovan
Jeffrey Donovan

8 January 2025 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
NANicole Asamoah
Nicole Asamoah
LGLara Gunton
Lara Gunton
Cutaneous pseudolymphoma refers to a group of skin conditions that simulate lymphoma either clinically and/or histologically. Cutaneous pseudolymphoma is a benign disorder that can often be misdiagnosed and has a wide range of treatment modalities. Currently, there is no gold standard of treatment, and the literature would benefit from more reports on successful and unsuccessful treatments of cutaneous pseudolymphoma. In this case, we present a 24-year-old female with cutaneous pseudolymphoma successfully treated with intralesional triamcinolone acetonide after misdiagnosis and several failures with other treatments.

1 November 2025 in Dermatitis®
Verified
Journal Article
Closed access
NANicole Asamoah
Nicole Asamoah
DBDevyani Bakshi
Devyani Bakshi
JBJoshua Buentiempo
Joshua Buentiempo
MAMohannad Abu-Hilal
Mohannad Abu-Hilal
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly affects patients’ quality of life (QoL). Limited data exists on the effects AD poses on sexual well-being. Objective: To evaluate the impact of moderate-to-severe atopic dermatitis (MtS-AD) on sexual well-being and assess the efficacy of advanced therapies, specifically abrocitinib and dupilumab, in improving sexual health. Methods: In this retrospective study, medical records and responses to an 8-item questionnaire assessing sexual well-being in patients with MtS-AD were reviewed at baseline and after 52 weeks of treatment with abrocitinib or dupilumab. Results: In total, 44 patients were included (mean age: 30.8, 43.2% female). Before treatment, 88.6% reported AD affected their sexual well-being, including feeling unattractive (79.5%), avoiding sexual activity (68.2%), feeling ashamed or embarrassed (68.2%), and experiencing rejection (56.8%). After 52 weeks of treatment with abrocitinib or dupilumab, these negative perceptions and behaviors significantly reduced. Conclusions: MtS-AD negatively impacts patients’ sexual well-being; however, advanced therapies like abrocitinib and dupilumab can significantly improve the sexual lives of affected patients, highlighting the broader benefits of these treatments on QoL.